AMENDMENTS

IN THE CLAIMS

Please amend claims 1 and 49 as shown below.

Please cancel claim 48 herein without prejudice to its renewal.

1. (Currently amended) A method for treating a hemoglobinopathy in a subject, the method comprising administering to the subject in need thereof a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase, wherein the compound is a structural mimetic of 2-oxoglutarate which increases expression of the gene encoding γ-globin in a bone marrow-derived cell, a hematopoietic stem cell, or a blast-forming unit erythroid cell, thereby treating the hemoglobinopathy in the subject.

2-11. (Previously Canceled)

12. (Previously presented) The method of claim 1, wherein the hemoglobinopathy comprises an alteration in the level, structural integrity, or activity of adult β-globin.

13. (Presently presented) The method of claim 1, wherein the hemoglobinopathy is selected from the group consisting of β-thalassemia and sickle cell syndrome.

14. (Previously presented) The method of claim 13, wherein the β-thalassemia is selected from the group consisting of β^0-thalassemia and β^+-thalassemia.

15. (Previously presented) The method of claim 13, wherein the sickle cell syndrome is selected from the group consisting of sickle trait, sickle β-thalassemia, and sickle cell anemia.

16. (Previously presented) The method of claim 1, wherein administering the compound increases the proportion of fetal hemoglobin relative to non-fetal hemoglobin produced by the bone marrow-derived cell, the hematopoietic stem cell, or the blast-forming unit erythroid cell.

17-47. (Previously Canceled)

48. (Canceled herein)

49. (Currently amended) The method of claim 1~~48~~, wherein the structural mimetic of 2-oxoglutarate inhibits HIF prolyl hydroxylase competitively with respect to 2-oxoglutarate and noncompetitively with respect to iron.